Frontage Laboratories, Inc. Establishes Joint Venture with Zhejiang Jiuzhou Pharmaceutical Co, Ltd. to Provide API Development and Manufacturing Services
July 27, 2016 at 11:35 am EDT
Share
Frontage Laboratories, Inc. announced that it has established a joint venture with Zhejiang Jiuzhou Pharmaceutical Co. Ltd. to provide enhanced access to high quality and economical API & intermediate development and manufacturing (CDMO) services to new US clients focused on New Chemical Entities (NCE) and vertically-integrated generic APIs that are developed through the combined efforts of Frontage and Jiuzhou. The venture, named FJ Pharma, LLC, will utilize Jiuzhou’s vast development and manufacturing infrastructures and experienced chemistry teams in China and Frontage’s API development team and CMC drug development services in the US. This relationship will help to efficiently support NCE development, more effectively reach clients interested in these services, and potentially offer vertically integrated finished products via Frontage’s affiliate drug product CDMO company, Frontida BioPharm, Inc. Jiuzhou and Frontage will continue to offer exceptional service to their existing clients following the formation of FJ Pharma.
Zhejiang Jiuzhou Pharmaceutical Co.,Ltd. is a China-based company principally engaged in the research, development, production and sales of chemical Active Pharmaceutical Ingredients (API) and intermediates. The Company mainly operates through two segments, including the New Drug and Intermediates Contract Development and Manufacturing Organization (CDMO) segment and the Specialty APIs and Intermediates segment. The New Drug and Intermediates CDMO segment mainly provides services for innovative medicines of pre-clinical chemical manufacturing and controls (CMC), clinical phases I, II and III, new drug application (NDA) and various stages after going public. The Specialty API and Intermediates segments mainly provides services including patent breakthroughs, production process improvement, drug certificate declaration, and cGMP standard commercial production for patented expired or soon-to-be-expired drugs for global chemical and generic drug manufacturers.
Frontage Laboratories, Inc. Establishes Joint Venture with Zhejiang Jiuzhou Pharmaceutical Co, Ltd. to Provide API Development and Manufacturing Services